{"id":15007,"date":"2024-09-30T14:29:00","date_gmt":"2024-09-30T08:59:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=15007"},"modified":"2024-10-30T10:41:41","modified_gmt":"2024-10-30T05:11:41","slug":"pompe-disease-emerging-therapies","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pompe-disease-emerging-therapies","title":{"rendered":"Pompe Disease: Causes, Symptoms, Diagnosis, Pathology, Current Marketed and Emerging Drugs in the Pipeline"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69cff8b0ad774\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69cff8b0ad774\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pompe-disease-emerging-therapies\/#Pompe_Disease_Current_Treatment_Landscape\" >Pompe Disease Current Treatment Landscape<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pompe-disease-emerging-therapies\/#Pompe_Disease_Emerging_Drugs\" >Pompe Disease Emerging Drugs<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pompe-disease-emerging-therapies\/#What_is_in_Store_for_Pompe_Disease\" >What is in Store for Pompe Disease?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pompe-disease-emerging-therapies\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Pompe disease is an inherited disorder caused by the buildup of a complex sugar called glycogen in the body&#8217;s cells. The accumulation of glycogen in certain organs and tissues, especially muscles, impairs their ability to function normally. There are three types of Pompe disease, which differ in severity and the age at which they appear. These types are known as <strong>classic infantile-onset, non-classic infantile-onset,<\/strong> and <strong>late-onset <\/strong>Pompe disease<strong>.<\/strong><\/p>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/pompe-disease-market\">Pompe disease<\/a> is caused due to mutations in the <strong><em>GAA<\/em> gene<\/strong>. The <em>GAA<\/em> gene provides instructions for producing an enzyme called acid alpha-glucosidase (also known as acid maltase). This enzyme is active in lysosomes which are structures that serve as recycling centers within cells. The enzyme normally breaks down glycogen into a simpler sugar called glucose, which is the main energy source for most cells. Mutations in the <em>GAA<\/em> gene prevent acid alpha-glucosidase from breaking down glycogen effectively, which allows this sugar to build up to toxic levels in lysosomes. This buildup damages organs and tissues throughout the body, particularly the muscles, leading to the progressive signs and symptoms of Pompe disease. Pompe disease is inherited in an autosomal recessive pattern which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition. There are many different and more scientific terms for Pompe Disease including <strong>Acid maltase deficiency, Alpha-1,4-glucosidase deficiency, GAA deficiency, Glycogenosis type II,<\/strong> and a few others.<\/p>\n\n\n\n<p>Pompe disease symptoms begin in the first months of life, with feeding problems, <strong>poor weight gain, muscle weakness, floppiness<\/strong>, and head lag. Respiratory difficulties are often complicated by lung infections. The heart is grossly enlarged. Many infants with Pompe disease also have enlarged tongues. Pompe disease affects about 1 in 40,000 people in the United States. The incidence of this disorder varies among different ethnic groups. Patients with the<strong> \u2018classic infantile\u2019<\/strong> form of Pompe disease are the most severely affected. Although hardly any symptoms may be apparent at birth, the disease usually presents within the first three months of life with rapidly progressive muscle weakness (\u2018floppy infants\u2019), diminished muscle tone (hypotonia), respiratory deficiency, and a type of heart disease known as hypertrophic cardiomyopathy, resulting in diminished cardiac function. These problems together culminate in cardio-respiratory failure within the first 2 years of life. Many infants have a large, protruding, tongue and moderate enlargement of the liver. The legs often rest in a frog position and feel firm on palpation.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><img decoding=\"async\" width=\"1024\" height=\"158\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30175345\/pompe-disease-symptoms-1024x158.png\" alt=\"pompe-disease-symptoms\" class=\"wp-image-29854\" style=\"width:840px;height:auto\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30175345\/pompe-disease-symptoms-1024x158.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30175345\/pompe-disease-symptoms-300x46.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30175345\/pompe-disease-symptoms-150x23.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30175345\/pompe-disease-symptoms-768x119.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30175345\/pompe-disease-symptoms-1536x237.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30175345\/pompe-disease-symptoms.png 1600w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>The diagnosis of Pompe disease is based on a thorough clinical evaluation, a detailed patient and family history, and a variety of biochemical tests with first of all the measuring of GAA activity. In individuals suspected of having Pompe disease, blood can be drawn and the function\/activity of GAA (the \u2018enzymatic activity\u2019) can be measured in white blood cells (leukocytes), but only if the proper assay conditions are being used and acarbose is added to the reaction mixture to inhibit the activity of glucoamylase. Alternatively, the GAA activity\/functional assay can also be performed on dried blood spots, but this method is not any quicker, less reliable, and also requires the use of acarbose to inhibit the glucoamylase activity. A variety of other tests can be performed to detect or assess symptoms potentially associated with <a href=\"https:\/\/www.delveinsight.com\/report-store\/pompe-disease-market\">Pompe disease<\/a> such as sleep studies, tests that measure lung function, and tests that measure muscle function. Muscle MRI (imaging by magnetic resonance) is used to visualize the degree of muscle damage.<\/p>\n\n\n\n<p>As per DelveInsight, the US accounted for nearly 65% of the <a href=\"https:\/\/www.delveinsight.com\/report-store\/pompe-disease-epidemiology-forecast\">total diagnosed prevalent cases of Pompe disease<\/a> across the 7MM in 2023, with the number expected to increase by 2034. In 2023, the diagnosed prevalent cases of Pompe disease in the US were approximately 8,600, with adult cases making up around 8,400. Among the EU4 and the UK, Germany had the highest number of diagnosed prevalent cases, followed by France. Japan, on the other hand, accounted for about 8% of the total diagnosed prevalent cases of Pompe disease within the 7MM in 2023, while Spain had the least diagnosed cases.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"415\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30145006\/Pompe-Disease-Market-Key-Insights-1024x415.png\" alt=\"\" class=\"wp-image-29801\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30145006\/Pompe-Disease-Market-Key-Insights-1024x415.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30145006\/Pompe-Disease-Market-Key-Insights-300x122.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30145006\/Pompe-Disease-Market-Key-Insights-150x61.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30145006\/Pompe-Disease-Market-Key-Insights-768x312.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30145006\/Pompe-Disease-Market-Key-Insights-1536x623.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30145006\/Pompe-Disease-Market-Key-Insights.png 1600w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Many key pharmaceuticals are proactively involved in developing <a href=\"https:\/\/www.delveinsight.com\/blog\/pompe-disease-treatment-market\">Pompe Disease treatment<\/a> therapies including companies like Immusoft, Asklepios Biopharmaceutical, Oxyrane, Maze Therapeutics, Amicus Therapeutics, Spark Therapeutics, and many others<\/p>\n\n\n\n<p>Currently, there is no permanent cure for Pompe disease. But different treatment options can help ease Pompe disease symptoms. Most patients require supportive therapy to address the symptoms which include respiratory and cardiac problems, physical disability, and difficulty swallowing. Some patients may require a mechanical ventilator during respiratory infections or at night. Physical and occupational therapy can improve patients\u2019 muscle strength and help them to learn to use canes or walkers if necessary. Speech therapy and the usage of feeding tubes are some of the other components.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pompe-disease-current-treatment-landscape\"><span class=\"ez-toc-section\" id=\"Pompe_Disease_Current_Treatment_Landscape\"><\/span><a href=\"https:\/\/www.delveinsight.com\/blog\/pompe-disease-treatment-market\"><strong>Pompe Disease Current Treatment Landscape<\/strong><\/a><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Pompe disease treatment is disease-specific, symptomatic, and supportive. Treatment requires the coordinated efforts of a team of specialists with expertise in treating neuromuscular disorders. Pediatricians or internists, neurologists, orthopedists, cardiologists, dieticians, and other healthcare professionals may need to systematically and comprehensively plan an affected child\u2019s treatment.&nbsp;<\/p>\n\n\n\n<p><strong>Enzyme Replacement Therapy (ERT)<\/strong> is a cornerstone in the <a href=\"https:\/\/www.delveinsight.com\/blog\/pompe-disease-treatment-market\"><strong>Pompe disease treatment<\/strong> landscape<\/a>. It involves the intravenous administration of recombinant human acid \u03b1-glucosidase. This therapy aims to boost the levels of GAA in the body and mitigate the excessive accumulation of glycogen inside cells. The enzyme, produced in the laboratory through genetically modified cultured cells, is purified and then introduced into the bloodstream. ERT helps alleviate the abnormal thickening of heart walls, a hallmark of <strong>Pompe disease<\/strong>, and supports muscle function, ultimately enhancing patients\u2019 quality of life.<\/p>\n\n\n\n<p>The advent of <strong>Pompe disease therapy<\/strong> through ERT has revolutionized the management of this condition, significantly altering its natural history, extending patient lifespan, and improving morbidity. Despite these advancements, results have not fully met expectations, and many patients still face challenges associated with the disease. Thus, <strong>treatment for Pompe disease<\/strong> often includes symptomatic and supportive measures. These may involve physical therapy to bolster strength, respiratory support via mechanical ventilation (such as BiPAP or volume ventilators) during respiratory infections, and other interventions like occupational therapy, which might include canes or walkers. Additionally, speech therapy can aid in improving articulation and communication for some patients. The ongoing support and comprehensive care are crucial for managing <strong>Pompe disease<\/strong> effectively and enhancing <strong>Pompe disease life expectancy with treatment<\/strong>.<\/p>\n\n\n\n<p>In April 2006, under priority review, the FDA approved a Biologic License Application for the orphan drug <a href=\"https:\/\/www.delveinsight.com\/blog\/pompe-disease-emerging-markets\">Myozyme <\/a>(alglucosidase alfa, recombinant human [rh] GAA) for patients with Pompe disease.&nbsp;<\/p>\n\n\n\n<p>Being the only FDA-approved curative treatment option for the disease it occupied a major market share despite its inherent adverse reactions including pneumonia, respiratory failure and distress, infections, and fever. This was the first disease-specific treatment for an inherited muscular disorder consisting of the intravenous administration of recombinant human GAA (Myozyme\/Lumizyme). Prior to the arrival of Enzyme replacement therapy (ERT) in 2006, patients were primarily dependent on Supportive Treatment comprising of respiratory support, ambulatory support, physiotherapy and\/or dietary treatment. Although historically, Supportive Care had been the mainstay of treatment (thereby generating a huge amount of revenue), but the approval and subsequent launch of ERT in 2006 after decades of research, helped turn the treatment landscape upside down, prompting a new era in the treatment of this disease.<\/p>\n\n\n\n<p>Although <strong>enzyme replacement therapy (ERT)<\/strong> is not a cure, it has played a critical role in slowing or halting the progression of <strong>Pompe disease<\/strong>. The introduction of ERT has marked a major therapeutic advancement, significantly benefiting patients by preventing further disease progression, despite its high cost. This has positioned ERT as a pivotal treatment option in managing Pompe disease.<\/p>\n\n\n\n<p>However, the landscape is evolving, and recent <a href=\"https:\/\/www.delveinsight.com\/blog\/pompe-disease-market\"><strong>advances in the Pompe disease market<\/strong><\/a> are expanding beyond ERT to include exciting <strong>new therapies<\/strong>. These emerging treatments, such as gene therapies and next-generation drugs, hold the potential to revolutionize patient care further, offering new hope for better management and possibly long-term solutions for those affected by Pompe disease. The shift from reliance on ERT to these <strong>new therapies<\/strong> reflects a broader transformation in the approach to treating Pompe disease.<\/p>\n\n\n\n<p>On August 06, 2021, the FDA approved NEXVIAZYME &nbsp; (avalglucosidase alfa-ngpt) for intravenous infusion to treat patients 1 year of age and older with late-onset Pompe disease to Genzyme Corporation. NEXVIAZYME, another Enzyme Replacement Therapy, is an intravenous medication that helps reduce glycogen accumulation. The effectiveness of NEXVIAZYME &nbsp; for the treatment of Pompe disease was demonstrated in a study of 100 patients who were randomized to take NEXVIAZYME &nbsp; or another FDA-approved enzyme replacement therapy for Pompe disease. The most common side effects included headache, fatigue, diarrhea, nausea, joint pain, dizziness, muscle pain, itching, vomiting, difficulty breathing, skin redness. In 2022, <strong>NEXVIAZYME&nbsp; <\/strong>&nbsp;was approved in Europe. By February 2024, new data indicated that treatment with <strong>NEXVIAZYME&nbsp; <\/strong>&nbsp;significantly improved ptosis, or drooping eyelid, in pediatric patients with <strong>infantile-onset Pompe disease<\/strong> (IOPD) over nearly three years.<\/p>\n\n\n\n<p>The currently approved rhGAA can significantly improve <a href=\"https:\/\/www.delveinsight.com\/blog\/pompe-disease-market\">Pompe disease\u2019s therapeutic effect<\/a>, in order to provide improved delivery of rhGAA to the lysosome, new technologies have been explored. Small molecule pharmacologic chaperones are currently being evaluated as therapeutic options in several single-gene disorders, including lysosomal storage disorders, where the pathology can be attributed to a misfolded but still functional enzyme, albeit, with reduced activity.<\/p>\n\n\n\n<p>In September 2023, the FDA approved <strong>POMBILITI<\/strong> (cipaglucosidase alfa-atga) + <strong>OPFOLDA\u2122<\/strong> (miglustat), marking a significant advancement in <strong>Pompe disease treatment<\/strong>. This groundbreaking two-component therapy combines <strong>POMBILITI\u2122<\/strong>, a bis-M6P-enriched recombinant human acid \u03b1-glucosidase (rhGAA) designed for high-affinity uptake through the M6P receptor while maintaining its potency, with <strong>OPFOLDA<\/strong>, an oral enzyme stabilizer that reduces the loss of enzyme activity in the bloodstream.<\/p>\n\n\n\n<p><strong>POMBILITI<\/strong> and <strong>OPFOLDA<\/strong> are specifically indicated for adults with <strong>late-onset Pompe disease<\/strong> (LOPD) who weigh 40 kg or more and have not achieved improvement with their current ERT. This new therapy represents a promising option for enhancing <strong>Pompe disease<\/strong> management and improving patient outcomes. In February 2024, the 20th Annual WORLDSymposium, awarded Amicus Therapeutics&#8217; POMBILITI + OPFOLDA the 2024 New Treatment Award.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"185\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30145108\/Key-Players-Working-in-the-Pompe-Disease-Treatment-Market-1024x185.png\" alt=\"\" class=\"wp-image-29802\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30145108\/Key-Players-Working-in-the-Pompe-Disease-Treatment-Market-1024x185.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30145108\/Key-Players-Working-in-the-Pompe-Disease-Treatment-Market-300x54.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30145108\/Key-Players-Working-in-the-Pompe-Disease-Treatment-Market-150x27.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30145108\/Key-Players-Working-in-the-Pompe-Disease-Treatment-Market-768x139.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30145108\/Key-Players-Working-in-the-Pompe-Disease-Treatment-Market-1536x277.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30145108\/Key-Players-Working-in-the-Pompe-Disease-Treatment-Market.png 1600w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Pompe_Disease_Emerging_Drugs\"><\/span><a href=\"https:\/\/www.delveinsight.com\/blog\/pompe-disease-emerging-markets\"><strong>Pompe Disease Emerging Drugs<\/strong><\/a><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>AT-GAA developed by <a href=\"https:\/\/www.delveinsight.com\/blog\/pompe-disease-emerging-markets\">Amicus Therapeutics<\/a> is an investigational therapy that consists of ATB200, a unique recombinant human acid alpha-glucosidase (rhGAA) enzyme with optimized carbohydrate structures, particularly mannose-6 phosphate (M6P), to enhance uptake, co-administered with AT2221, a pharmacological chaperone. In Feb 2019, the US Food and Drug Administration (FDA) granted Amicus a Breakthrough Therapy Designation&nbsp; to AT-GAA for the treatment of late-onset Pompe disease. In February 2023, Amicus Therapeutics announced positive results from the global Phase 3 open-label extension (OLE) study (ATB200-07), which is currently ongoing. This study assessed the long-term efficacy and safety of <strong>AT-GAA<\/strong> in adults with late-onset Pompe disease. The results showed that participants treated with <strong>AT-GAA<\/strong> for up to 104 weeks exhibited persistent and durable improvements in six-minute walk distance (6MWD), stability in forced vital capacity (FVC), and continued reductions in biomarkers of muscle damage and disease substrate.<\/p>\n\n\n\n<p><strong>Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase<\/strong> is being developed by <strong>Lacerta Therapeutics, Inc.<\/strong> and is currently in the <strong>Phase I stage<\/strong> of development.<\/p>\n\n\n\n<p>Another Pompe disease gene therapy <strong>ACTUS-101<\/strong> currently being developed by <a href=\"https:\/\/www.delveinsight.com\/blog\/pompe-disease-emerging-markets\"><strong>Actus Therapeutics<\/strong><\/a><strong> <\/strong>is delivered into the blood, specifically targeting the liver to promote the production of the GAA enzyme. However, it is in an early stage of development and recently dosed the first patient for the <strong>Phase I\/II trial<\/strong>. It would be too soon to predict the impact it will have on the market if and once approved.<\/p>\n\n\n\n<p><strong>VAL-1221 <\/strong>being developed by <strong>Valerion Therapeutics<\/strong> is a recombinant fusion protein comprised of rhGAA and a lupus anti-DNA antibody 3E10 with GAA (acid glucosidase), the missing enzyme in GSD Type II (that is believed to utilize the nucleoside transporter ENT2 for cellular uptake of ERT in an M6P-independent manner). The drug candidate is currently in<strong> Phase I\/II stage<\/strong> of clinical development by Valerion Therapeutics for the treatment of late-onset Pompe disease.<\/p>\n\n\n\n<p>AT845 by Audentes Therapeutics (now a part of Astellas) is a <a href=\"https:\/\/www.delveinsight.com\/report-store\/pompe-disease-pipeline-insight\">novel Pompe disease product candidate <\/a>expected to address the recognized limitations of ERT by facilitating the intracellular production of GAA to improve efficacy, reduce immunogenicity, and deliver a durable and transformative clinical benefit from a single intravenous administration. Currently, <strong>AT845<\/strong> is in Phase I\/II clinical trials for LOPD. In February 2023, Astellas announced preliminary results from the Phase I\/II first-in-human clinical trial, FORTIS, which assessed the safety, tolerability, and exploratory efficacy of <strong>AT845<\/strong> in adults with LOPD. These results were presented at the 19th Annual WORLDSymposium in Orlando.<\/p>\n\n\n\n<p><strong>GC301<\/strong>, developed by Beijing GeneCradle Pharmaceutical, is another promising drug in the pipeline for infantile-onset Pompe disease (IOPD). This gene therapy utilizes a recombinant adeno-associated virus (AAV) to deliver the GAA gene expression sequence systemically. The therapy has received notification of drug clinical trial approval from the Center for Drug Evaluation, National Medical Products Administration (CDE-NMPA), and has been approved by the clinical trial ethics committee of Peking Union Medical College Hospital (PUMCH). GC301 is currently in Phase I\/II clinical trials, but the studies are exclusively conducted in China.<\/p>\n\n\n\n<p>The biotech companies <strong>Shire <\/strong>and <strong>NanoMedSyn <\/strong>launched a new research partnership to evaluate a potential treatment for lysosomal storage disorders including Pompe disease.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table><tbody><tr><td><strong>Company Name<\/strong><\/td><td><strong>Emerging Drugs<\/strong><\/td><td><strong>Clinical Trial Phase<\/strong><\/td><\/tr><tr><td>Amicus Therapeutics<\/td><td>AT-GAA<\/td><td>Phase I\/II<\/td><\/tr><tr><td>GeneCradle Pharmaceutical<\/td><td>GC301<\/td><td>Phase I\/II<\/td><\/tr><tr><td>Actus Therapeutic<\/td><td>ACTUS-101<\/td><td>Phase I\/II<\/td><\/tr><tr><td>Audentes Therapeutics<\/td><td>AT845<\/td><td>Phase I\/II<\/td><\/tr><tr><td>Valerion Therapeutics<\/td><td>VAL-1221<\/td><td>Phase I\/II<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_in_Store_for_Pompe_Disease\"><\/span><strong>What is in Store for Pompe Disease<\/strong>?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>There are many key pharmaceutical players in the <a href=\"https:\/\/www.delveinsight.com\/blog\/pompe-disease-treatment-market\">Pompe Disease therapeutic market landscape<\/a> such as Sanofi, Actus, Amicus, Roche, and others which are anticipated to develop novel and potential treatment therapies which will enhance treatment outcomes in Pompe patients. In addition to that, investigational gene therapies have the potential to provide a long-term, steady supply of GAA enzymes to the entire body through one-time administration. These kinds of new and innovative researches provide hope for a bright future for the treatment of Pompe Disease.<\/p>\n\n\n\n<p>Also, recently the FDA has been granting many drugs Priority Review,&nbsp; Fast Track &amp;&nbsp; Breakthrough Therapy designations which may provide incentives to assist and encourage the development of drugs for rare diseases.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/pompe-disease-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30145146\/Pompe-Disease-Market-Outlook-1024x194.png\" alt=\"\" class=\"wp-image-29803\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30145146\/Pompe-Disease-Market-Outlook-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30145146\/Pompe-Disease-Market-Outlook-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30145146\/Pompe-Disease-Market-Outlook-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30145146\/Pompe-Disease-Market-Outlook-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30145146\/Pompe-Disease-Market-Outlook-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30145146\/Pompe-Disease-Market-Outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1640346582360\"><strong class=\"schema-faq-question\"><strong>What is Pompe disease life expectancy?<\/strong><\/strong> <p class=\"schema-faq-answer\">Life expectancy for late-onset Pompe disease is currently estimated to be age 30 when it first appears in children or teenagers, and 50 years of age for adults. But the infantile form of Pompe disease is extremely serious and usually fatal with a life expectancy of less than 2 years.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1640346606894\"><strong class=\"schema-faq-question\"><strong>Can Pompe disease be cured?<\/strong><\/strong> <p class=\"schema-faq-answer\">Unfortunately, there is no cure for Pompe disease. However, Pompe disease has benefited from the introduction of enzyme replacement therapy (ERT), which, although expensive, is a major therapeutic advance.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1640346629998\"><strong class=\"schema-faq-question\"><strong>Is Pompe disease more common in males or females?<\/strong><\/strong> <p class=\"schema-faq-answer\">The disease is rare. In the United States, only 1 person in 40,000 is affected by Pompe disease. It can affect both males and females of all ethnic groups.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Pompe disease is an inherited disorder caused by the buildup of a complex sugar called glycogen in the body&#8217;s cells. The accumulation of glycogen in certain organs and tissues, especially muscles, impairs their ability to function normally. There are three types of Pompe disease, which differ in severity and the age at which they appear. [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":29824,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[489,4640,4540,4556,4541],"industry":[17225],"therapeutic_areas":[17234,17243],"class_list":["post-15007","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-pompe-disease","tag-pompe-disease-emerging-markets","tag-pompe-disease-market","tag-pompe-disease-pipeline","tag-pompe-disease-therapy-market","industry-pharmaceutical","therapeutic_areas-rare-diseases","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pompe Disease Therapeutic Pipeline Landscape<\/title>\n<meta name=\"description\" content=\"Pompe Disease market key players like Sanofi, Actus, Amicus anticipated to develop novel therapies in order to enhance treatment outcomes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pompe-disease-emerging-therapies\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pompe Disease Therapeutic Pipeline Landscape\" \/>\n<meta property=\"og:description\" content=\"Pompe Disease market key players like Sanofi, Actus, Amicus anticipated to develop novel therapies in order to enhance treatment outcomes.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pompe-disease-emerging-therapies\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-09-30T08:59:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-30T05:11:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30155637\/Pompe-Disease-Pillar-article.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"12 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pompe Disease Therapeutic Pipeline Landscape","description":"Pompe Disease market key players like Sanofi, Actus, Amicus anticipated to develop novel therapies in order to enhance treatment outcomes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pompe-disease-emerging-therapies","og_locale":"en_US","og_type":"article","og_title":"Pompe Disease Therapeutic Pipeline Landscape","og_description":"Pompe Disease market key players like Sanofi, Actus, Amicus anticipated to develop novel therapies in order to enhance treatment outcomes.","og_url":"https:\/\/www.delveinsight.com\/blog\/pompe-disease-emerging-therapies","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-09-30T08:59:00+00:00","article_modified_time":"2024-10-30T05:11:41+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30155637\/Pompe-Disease-Pillar-article.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/pompe-disease-emerging-therapies","url":"https:\/\/www.delveinsight.com\/blog\/pompe-disease-emerging-therapies","name":"Pompe Disease Therapeutic Pipeline Landscape","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pompe-disease-emerging-therapies#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pompe-disease-emerging-therapies#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30155637\/Pompe-Disease-Pillar-article.png","datePublished":"2024-09-30T08:59:00+00:00","dateModified":"2024-10-30T05:11:41+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Pompe Disease market key players like Sanofi, Actus, Amicus anticipated to develop novel therapies in order to enhance treatment outcomes.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/pompe-disease-emerging-therapies#faq-question-1640346582360"},{"@id":"https:\/\/www.delveinsight.com\/blog\/pompe-disease-emerging-therapies#faq-question-1640346606894"},{"@id":"https:\/\/www.delveinsight.com\/blog\/pompe-disease-emerging-therapies#faq-question-1640346629998"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pompe-disease-emerging-therapies"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pompe-disease-emerging-therapies#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30155637\/Pompe-Disease-Pillar-article.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30155637\/Pompe-Disease-Pillar-article.png","width":466,"height":284,"caption":"An Exploratory Analysis of the Rare and Inherited Pompe Disease"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/pompe-disease-emerging-therapies#faq-question-1640346582360","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/pompe-disease-emerging-therapies#faq-question-1640346582360","name":"What is Pompe disease life expectancy?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Life expectancy for late-onset Pompe disease is currently estimated to be age 30 when it first appears in children or teenagers, and 50 years of age for adults. But the infantile form of Pompe disease is extremely serious and usually fatal with a life expectancy of less than 2 years.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/pompe-disease-emerging-therapies#faq-question-1640346606894","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/pompe-disease-emerging-therapies#faq-question-1640346606894","name":"Can Pompe disease be cured?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Unfortunately, there is no cure for Pompe disease. However, Pompe disease has benefited from the introduction of enzyme replacement therapy (ERT), which, although expensive, is a major therapeutic advance.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/pompe-disease-emerging-therapies#faq-question-1640346629998","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/pompe-disease-emerging-therapies#faq-question-1640346629998","name":"Is Pompe disease more common in males or females?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The disease is rare. In the United States, only 1 person in 40,000 is affected by Pompe disease. It can affect both males and females of all ethnic groups.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30155637\/Pompe-Disease-Pillar-article-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pompe Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pompe disease Emerging markets<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pompe disease market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pompe Disease Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pompe disease therapy market<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Pompe Disease<\/span>","<span class=\"advgb-post-tax-term\">Pompe disease Emerging markets<\/span>","<span class=\"advgb-post-tax-term\">Pompe disease market<\/span>","<span class=\"advgb-post-tax-term\">Pompe Disease Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Pompe disease therapy market<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Sep 30, 2024","modified":"Updated on Oct 30, 2024"},"absolute_dates_time":{"created":"Posted on Sep 30, 2024 2:29 pm","modified":"Updated on Oct 30, 2024 10:41 am"},"featured_img_caption":"An Exploratory Analysis of the Rare and Inherited Pompe Disease","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/15007","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=15007"}],"version-history":[{"count":7,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/15007\/revisions"}],"predecessor-version":[{"id":30194,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/15007\/revisions\/30194"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/29824"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=15007"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=15007"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=15007"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=15007"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=15007"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}